
Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.
MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.
MDMA-assisted therapy went through the wringer this past year. What seemed to be leading up to a monumental breakthrough in psychiatry resulted instead in a setback for integrating psychedelics into the treatment paradigm for






